Interpretation of 2023 2nd NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma
10.16139/j.1007-9610.2024.01.03
- VernacularTitle:2023年第2版《NCCN胰腺癌临床实践指南》更新解读
- Author:
Jiahao CHEN
1
;
Chongyi JIANG
Author Information
1. 复旦大学附属华东医院肝胆胰脾外科,上海 200040
- Keywords:
Pancreatic adenocarcinoma;
National Comprehensive Cancer Network(NCCN);
Guideline;
Interpretation
- From:
Journal of Surgery Concepts & Practice
2024;29(1):10-13
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic adenocarcinoma,a severe digestive malignancy,is characterized by its poor prognosis.The National Comprehensive Cancer Network(NCCN)persistently refines its guidelines,integrating cutting-edge evidence-based medical insights to standardize the diagnostic and therapeutic strategies of pancreatic adenocarcinoma.The NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma were updated twice on May 4 and June 19,2023,respectively.Compared to the 2022 predecessor,these two updates placed a particular emphasis on immunotherapy/targeted therapy,the introduction of NALIRIFOX regimen,and supplementary treatment protocols for patients with intermediate performance status.This article provided an interpretation of the latest updates to the NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma,integrating relevant evidence-based medical findings.
